Target General Information
Target ID T43189
Target Name Tubulin
Synonyms Tubulin beta-4 chain; Tubulin beta-III; TUBB3
Target Type Successful
Gene Name TUBA1C
Biochemical Class Tubulin family
UniProt ID TBA1A_HUMAN||TBA1B_HUMAN||TBA1C_HUMAN||TBA3C_HUMAN||TBA3E_HUMAN||TBA4A_HUMAN||TBA8_HUMAN||TBB1_HUMAN||TBB2A_HUMAN||TBB2B_HUMAN||TBB3_HUMAN||TBB4A_HUMAN||TBB4B_HUMAN||TBB5_HUMAN||TBB6_HUMAN||TBB8_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Breast cancer
Example drug Cabazitaxel Approved [531351], [541879], [1572592]
Tissue Breast tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.30
Z-score: 0.59
P-value: 4.29E-15
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.24
Z-score: 0.38
P-value: 3.00E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Rheumatoid arthritis
Example drug Colchicine Approved [538354], [542532], [551871], [1572592]
Tissue Synovial tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.71
Z-score: 1.23
P-value: 4.60E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Ovarian cancer
Example drug Epothilon Phase 3 [536839], [1572592]
Tissue Ovarian tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.35
Z-score: 0.43
P-value: 7.94E-02
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 1.00
Z-score: 0.60
P-value: 7.32E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Bladder cancer
Example drug Larotaxel Discontinued in Phase 3 [546774], [1572592]
Tissue Bladder tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.12
Z-score: -0.23
P-value: 4.53E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Disease Lung cancer
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 0.28
Z-score: 0.72
P-value: 5.46E-09
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 0.17
Z-score: 0.34
P-value: 1.54E-02
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Sarcoma
Tissue Muscle tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.86
Z-score: 3.42
P-value: 2.73E-287
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: 2.06
Z-score: 4.67
P-value: 2.24E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref
Ref 546774Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
Ref 538354FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 084279.
Ref 541879(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
Ref 542532(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7526).
Ref 536839Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
Ref 531351Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.